LindholmB., NorbechH.E.Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis.Acta Med Scand1986; 220: 143–51.
2.
KeaneW.F.Lipids and the kidney.Kidney Int1994; 46: 910–20.
3.
FriedL., HutchisonA., StegmayrB., PrichardS., BargmanJ.M.Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis.Perit Dial Int1999; 19: 7–16.
4.
LameireN., MatthysD., MatthysE., BeheydtR.Effects of long term CAPD on carbohydrate and lipid metabolism.Clin Nephrol1988; 30(Suppl 1): S53–8.
5.
MistryC.D., GokalR., PeersE., and MIDAS Study Group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD.Kidney Int1994; 46: 496–503.
6.
BredieS.J., BoschF.H., DemackerP.N., StalenhoefA.F., van LeusenR.Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism.Perit Dial Int2001; 21: 275–81.
7.
LittleJ., PhillipsL., RussellL.Longitudinal lipid profiles on CAPD: Their relationship to weight gain, comorbidity, and dialysis factors.J Am Soc Nephrol1998; 9: 1931–9.
8.
TurganC., FeehallyJ., BennettS., DaviesT.J., WallsJ.Accelerated hypertriglyceridemia in patients on continuous ambulatory peritoneal dialysis — a preventable abnormality.Int J Artif Organs1981; 4: 158–60.
